Oncotelic net loss widens to $1.9 million in Q2 FY26; revenue totals $250,000

Reuters2026/08/13 21:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oncotelic posted a GAAP net loss of $1.9 million for the six months ended June 30, 2026, versus a $153,815 loss a year earlier.
Revenue was $250,000, reflecting services provided to Lunai under an IP Services Agreement.
Operating loss widened to $2.7 million as operating expense climbed to $2.95 million, driven by higher stock-based compensation and legal fees.
Cash totaled $206,000 with working capital at a $16.45 million deficit, while management flagged substantial doubt about going-concern status.
It kept its 45% stake in GMP Bio at a $365.4 million fair value, citing no material changes since Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037857), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncotelic net loss widens to $1.9 million in Q2 FY26; revenue totals $250,000

You may also like

Crypto prices